Skip to main content

Clinical trial CAPItello-281

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)

Organ prostate
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor AstraZeneca
EudraCT Identifier 2020-000346-33
Last update